Table 1. Univariate and multivariate analysis of GNA13 expression and various clinicopathological parameters in training and validation cohort patients with G.
| Variables | Training cohort | Validation cohort | ||||||
|---|---|---|---|---|---|---|---|---|
| Case | HR | (95% CI) | P value | Case | HR | (95% CI) | P value | |
| Univariate analysis | ||||||||
| Age | ||||||||
| < 60yr | 149 | 1 | 113 | 1 | ||||
| ≥ 60yr | 84 | 1.47 | 0.998–2.166 | 0.051 | 80 | 1.259 | 0.805–1.968 | 0.313 |
| Gender | ||||||||
| Male | 152 | 1 | 127 | 1 | ||||
| Female | 81 | 1.057 | 0.708–1.578 | 0.785 | 66 | 1.230 | 0.780–1.942 | 0.373 |
| T status | ||||||||
| T1/2 | 47 | 1 | 45 | 1 | ||||
| T3/4 | 186 | 8.838 | 3.250–24.036 | < 0.001 | 148 | 3.351 | 1.610–6.973 | 0.001 |
| N | ||||||||
| N0 | 65 | 1 | 63 | 1 | ||||
| N1/2 | 168 | 5.034 | 2.621–9.667 | < 0.001 | 130 | 6.309 | 3.027–13.150 | < 0.001 |
| M | ||||||||
| M0 | 213 | 1 | 159 | 1 | ||||
| M1 | 20 | 3.93 | 2.316–6.667 | < 0.001 | 34 | 3.468 | 2.128–5.652 | < 0.001 |
| Clinical stage | ||||||||
| I/II | 77 | 1 | 70 | 1 | ||||
| III/IV | 156 | 7.012 | 3.648–13.476 | < 0.001 | 123 | 6.511 | 3.240–13.082 | < 0.001 |
| Grade | ||||||||
| G1/2 | 69 | 1 | 47 | 1 | ||||
| G3 | 164 | 1.676 | 1.055–2.662 | 0.029 | 146 | 2.252 | 1.216–4.170 | 0.010 |
| Tumor size | ||||||||
| < 4 cm | 120 | 1 | 124 | 1 | ||||
| ≥ 4 cm | 113 | 1.845 | 1.249–2.726 | 0.002 | 69 | 1.689 | 1.079–2.644 | 0.022 |
| Therapy | ||||||||
| Surgery only | 108 | 1 | 84 | |||||
| Surgery + CT | 125 | 1.378 | 0.931–2.040 | 0.109 | 109 | 0.899 | 0.566–1.429 | 0.654 |
| Ki-67 expression | ||||||||
| < 50% | 135 | 1 | 116 | 1 | ||||
| ≥ 50% | 98 | 4.137 | 2.734–6.261 | < 0.001 | 77 | 1.629 | 1.044–2.541 | 0.032 |
| GNA13 expression | ||||||||
| Low expression | 140 | 1 | 103 | 1 | ||||
| High expression | 93 | 8.244 | 5.219–13.023 | < 0.001 | 90 | 3.176 | 1.979–5.096 | < 0.001 |
| Multivariate analysis | ||||||||
| T status | ||||||||
| T1/2 | 47 | 1 | 45 | 1 | ||||
| T3/4 | 186 | 3.411 | 1.207–9.642 | 0.021 | 148 | 1.544 | 0.711–3.356 | 0.272 |
| N | ||||||||
| N0 | 65 | 1 | 63 | 1 | ||||
| N1/2 | 168 | 2.137 | 1.070–4.270 | 0.031 | 130 | 4.021 | 1.878–8.608 | < 0.001 |
| M | ||||||||
| M0 | 213 | 1 | 159 | 1 | ||||
| M1 | 20 | 2.546 | 1.455–4.455 | 0.001 | 34 | 2.771 | 1.655–4.639 | < 0.001 |
| Grade | ||||||||
| G1/2 | 69 | 1 | 47 | 1 | ||||
| G3 | 164 | 1.252 | 0.769–2.036 | 0.366 | 146 | 2.361 | 1.249–4.465 | 0.008 |
| Tumor size | ||||||||
| < 4 cm | 120 | 1 | 124 | 1 | ||||
| ≥ 4 cm | 113 | 1.297 | 0.872–1.930 | 0.199 | 69 | 1.097 | 0.691–1.742 | 0.695 |
| Ki-67 expression | ||||||||
| < 50% | 135 | 1 | 116 | 1 | ||||
| ≥ 50% | 98 | 1.189 | 0.653–2.165 | 0.572 | 77 | 0.912 | 0.543–1.533 | 0.729 |
| GNA13 expression | ||||||||
| Low expression | 140 | 1 | 103 | 1 | ||||
| High expression | 93 | 4.871 | 2.495–9.510 | < 0.001 | 90 | 3.135 | 1.819–5.401 | < 0.001 |
GC, gastric cancer; CT,chemotherapy; Cox propotional hazard regression model, enter; HR, Hazard ratio; CI, confidence interval.